Gamida Cell Ltd. - Ordinary Shares (GMDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
GMDA Stock Price Chart Interactive Chart >
GMDA Price/Volume Stats
|Current price||$1.73||52-week high||$6.84|
|Prev. close||$1.75||52-week low||$1.71|
|Day high||$1.76||Avg. volume||774,934|
|50-day MA||$2.29||Dividend yield||N/A|
|200-day MA||$3.13||Market Cap||102.42M|
Gamida Cell Ltd. - Ordinary Shares (GMDA) Company Bio
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Most Popular Stories View All
GMDA Latest News Stream
|Loading, please wait...|
GMDA Latest Social Stream
View Full GMDA Social Stream
Latest GMDA News From Around the Web
Below are the latest news stories about Gamida Cell Ltd that investors may wish to consider to help them evaluate GMDA as an investment opportunity.
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.
Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.
Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.
GMDA Price Returns